Breaking News

Drugmakers see a pricing blueprint in an $850,000 gene therapy

Stock MarketsJan 12, 2018 05:41PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
© Reuters. A man receives an eye exam

By Caroline Humer

SAN FRANCISCO (Reuters) - Global drugmakers are looking to a tiny biotech's $850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines.

Spark Therapeutics Inc (O:ONCE) plans to launch its recently approved Luxturna treatment for an inherited genetic mutation that causes blindness in March. The drug is to be administered only once, by injection, and Spark plans to charge $425,000 per eye, an unprecedented price.

But what is grabbing the attention of other drugmakers is not just what might be called an eye-popping price to treat a condition that Spark estimates affects 1,000 to 2,000 people in the United States, but the ways Spark is looking to help payers ranging from the federal government to private insurers absorb the drug's high cost, including spreading out payments over several years.

"We're laying the groundwork for the future of our pipeline and the future of one-time curative gene therapy treatments," Spark's chief executive officer, Jeffrey Marrazzo, said in an interview at the JPMorgan (NYSE:JPM) Healthcare Conference in San Francisco this week.

The high cost of prescription drugs has become an increasingly critical and contentious issue.

The independent Institute for Clinical and Economic Review (ICER) issued a report on Friday saying the proposed Luxturna price was far too high in most cases.

Healthcare spending accounts for 18 percent of the U.S. economy and has been rising faster than the rate of inflation as drugs and medical services costs increase. An influx of very expensive drugs that offer a one-time cure – such as a hepatitis C treatment from Gilead Sciences Inc (O:GILD) – has already stretched state and federal budgets.

The U.S. Centers for Medicare and Medicaid Services (CMS), which provides coverage for 125 million elderly, poor and disabled Americans, spends hundreds of billions of dollars annually on medicines.

CMS is trying to tackle the overall high drug costs. It has asked for input from private health insurers and drugmakers on payment models that are expected to influence how medical breakthroughs for millions more patients are covered. 

Spark itself is working with CMS on a legal structure to allow government and private-sector health plans to pay for Luxturna, which restores some vision for most patients with the inherited mutation, over several years, rather than in a single payment, without hurting its profits.

Spark has also offered refunds if the treatment stops working and ways for payers to buy the drug outside of hospitals, which can significantly mark up the price of a medicine administered in their facilities.

In interviews with Reuters, executives from large drugmakers including Eli Lilly & Co (N:LLY), GlaxoSmithKline Plc (L:GSK), Roche Holding AG (S:ROG), Merck & Co Inc (N:MRK) and Bristol-Myers Squibb Co (N:BMY) said they would pay close attention to the outcome of Spark's payment discussions.

They are also following two revolutionary gene-based therapies for blood cancers from Novartis AG (S:NOVN) and Gilead Sciences. Novartis' Kymriah, with a list price of $475,000, is covered by CMS based on outcomes achieved for pediatric and young adult leukemia patients by the end of the first month of treatment.

Spark is also looking at guaranteeing its product. It is working on a plan with pharmacy benefits manager Express Scripts Holding Co (O:ESRX) on a long-term payment schedule for privately insured patients.

Spark plans to sell Luxturna through specialty pharmacies, including one owned by Express Scripts, so that large employers and health plans can avoid hospital markups that could reach hundreds of thousands of dollars. Express Scripts is working with Spark on provisions to refund money to insurers if the drug does not work as promised.

"Spark is willing to guarantee its product over a period of time and potentially extend that payment over a period of time; it needs someone to be a chassis," Express Scripts CEO Tim Wentworth said.


Large drugmakers already offer refunds on some drugs, including treatments for diabetes or high cholesterol, if they do not provide a benefit.

But it is tougher to create a long-term payment model for a very expensive drug administered only once. The U.S. system is built to cover the whole cost immediately, and CMS needs to determine how smaller payments could be made without triggering bigger-than-intended discounts.

CMS does not negotiate prices or purchase drugs, but it sets ground rules for the managed care companies and state Medicaid agencies that do. CMS chief Seema Verma told Reuters last year that she was looking at new payment models for high-priced breakthrough treatments.

Another road block under discussion: Patients often change insurance, or move between private and government-sponsored health coverage depending on their age or employment status. Under a deferred payment plan, the government could be billed for patients who they no longer cover.

"The innovation is there, but the financing vehicles need to catch up," said Jack Bailey, GlaxoSmithKline's U.S. pharmaceuticals head.  

Paul Biondi, head of business development at Bristol-Myers, said the drugmaker is closely following the payment outcome for gene therapies. "I'm glad other people are plowing the ground," he said.

The next U.S.-approved gene therapy may come from Bluebird Bio (O:BLUE). The small biotech company expects to submit this year a potentially one-time treatment for the inherited blood disorder beta thalassemia, which can cause severe anemia. Bluebird also aims to seek approval for a gene-based cancer therapy in 2019.

"We've been thinking about pricing for years," Jeffrey Walsh, Bluebird's chief financial and strategy officer, said. "Now we can bring in the regulators."

The company is talking to the U.S. government, as well as governments in the UK, France, Germany and Italy, about pricing over a period of time and how to prove a drug is working.

"The system in the U.S. isn't built for a single intervention," Walsh said.

Drugmakers see a pricing blueprint in an $850,000 gene therapy

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Are you sure you want to delete this chart?
Write your thoughts here
Replace the attached chart with a new chart ?
Post also to:
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Post 1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email